Application of natural killer T cells in antitumor immunotherapy

Area of Science:

• Immunology
• Oncology
• Cellular Biology

Background:

• Natural killer T (NKT) cells are a distinct T cell subset recognizing glycolipid antigens via CD1d molecules.
• NKT cells possess dual Th1/Th2 cytokine production capabilities and are integral to immune response regulation.
• These cells actively participate in spontaneous tumor immunosurveillance.

Purpose of the Study:

• To review NKT cell-mediated antitumor immune responses.
• To discuss the outcomes and implications of recent clinical studies involving NKT cell activation.
• To highlight the potential of NKT cells as a target for anticancer immunotherapies.

Main Methods:

• Review of scientific literature on NKT cell function and activation.
• Analysis of data from clinical trials using alpha-GalCer and NKT cell-based therapies.
• Discussion of various CD1d ligands and their impact on NKT cell activation.

Main Results:

• Activation of NKT cells with alpha-Galactosylceramide (alpha-GalCer) elicits potent antitumor immunity.
• NKT cell activation involves direct cytotoxicity and indirect recruitment of NK cells and CD8+ T cells.
• Diverse CD1d ligands, including self, bacterial, and synthetic glycolipids, can activate NKT cells.

Conclusions:

• The ability to control NKT cell activation positions them as a prime target for novel anticancer immunotherapies.
• Clinical trials with alpha-GalCer have yielded both encouraging and challenging results, necessitating further investigation.
• Understanding NKT cell activation is crucial for advancing effective cancer treatments.